Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

Inclusion Criteria: * Participant is ≥40 kg and ≤120 kg weight * Participant and participant's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations. * Previously documented CHC genotype 4 infection * Liver biopsy or fibrotest and fibroscan with histology consistent with CHC and no other etiology and with hepatic fibrosis scores (F0, F1, F2, F3). Exclusion Criteria: * Co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus * Treatment for hepatitis C with any investigational medication * Treatment with any investigational drug within 30 days of the screening visit * Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy * Autoimmune hepatitis or a history of autoimmune disease * Hepatic fibrosis score F4 * Severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease in the previous six months * Autoimmune hepatitis or a history of autoimmune disease * Thyroid disease uncontrolled with conventional treatment * Epilepsy and/or compromised central nervous system (CNS) function